Clinical Trial Update: A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate the safety, immunogenicity, and pharmacokinetics of GR2102 in healthy adults for respiratory syncytial virus infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• GR2102

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: UNKNOWN